Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17957279 | 0.95 | MCHR1 (0.45) | MCHR1NTRK1NTRK2MTORALDH1A1 | |
| SCHEMBL13133028 | 0.93 | MCHR1 (0.42) | MCHR1NTRK1NTRK2MTORCACNA1G | |
| SCHEMBL2815670 | 0.89 | NTRK1 (0.40) | NTRK1NTRK2PARP1ALDH1A1EPHX2 | |
| SCHEMBL17957276 | 0.89 | MCHR1 (0.40) | MCHR1NTRK1NTRK2MTORTRPV1 | |
| SCHEMBL2813663 | 0.88 | MCHR1 (0.45) | MCHR1NTRK1NTRK2MTORALDH1A1 | |
| SCHEMBL2814671 | 0.88 | NTRK1 (0.45) | MCHR1NTRK1NTRK2MTORTRPV1 | |
| SCHEMBL2819331 | 0.86 | ROCK1 (0.49) | MCHR1NTRK1NTRK2TRPV1 | |
| SCHEMBL17957281 | 0.84 | MCHR1 (0.43) | MCHR1NTRK1NTRK2MTORALDH1A1 | |
| SCHEMBL2818198 | 0.83 | MCHR1 (0.40) | MCHR1NTRK1NTRK2MTOR | |
| SCHEMBL13133022 | 0.82 | PARP1 (0.41) | NTRK1NTRK2PARP1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | MCHR1 4238/4885NTRK1 3535/4885NTRK2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.